ClinicalTrials.gg
Not yet recruitingNCT07585383Updated May 15, 2026

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects

A Phase 1 interventional study of KR23248 and Matching Placebo in Schizophrenia, sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China. It will enroll male and female participants aged 18 years to 45 years.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, dose-escalating Phase I trial, aiming to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of single and multiple oral doses of KR23248 capsules in healthy adult subjects. The study consists of two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies.

The single ascending dose study plans to enroll 54 healthy subjects, with predefined dose escalation levels of 0.5 mg, 1.0 mg, 2.0 mg, 3.0 mg, 4.5 mg, and 6.0 mg in sequence. The multiple ascending dose study sets the initial dose at 2.0 mg, with 12 healthy subjects planned for enrollment.

02

Conditions studied

  • Schizophrenia

Browse trials for

03

In context

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

This study's planned enrollment of 66 is close to the median of 70 across 2,953 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male/female subjects aged ≥ 18 years and ≤ 45 years (inclusive) at the time of signing the form.
  2. (BMI) ranging from 18.5 to 28.0 kg/m² (inclusive) at screening; male subjects with body weight ≥50 kg and female subjects with body weight ≥45 kg.
  3. Subjects who voluntarily participate in the trial and sign the informed consent form after understanding the purpose, content, procedures, and potential risks of the trial.
  4. Subjects who can communicate well with the investigators, are willing and able to comply with lifestyle restrictions specified in the protocol, and cooperate with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any diseases or dysfunctions in present illness and medical history that may interfere with the clinical trial, including but not limited to neurological and psychiatric diseases, cardiovascular diseases (e.g., congenital long syndrome), urinary system disorders, digestive system disorders, respiratory system disorders, musculoskeletal system disorders, metabolic and endocrine system disorders, skin diseases, hematological diseases, immune system diseases, and tumors.
  2. Subjects with any surgical condition or medical history that may significantly affect drug absorption, distribution, metabolism and excretion, or may pose a risk to the subject participating in the trial; such as a history of gastrointestinal surgery (gastrectomy, gastroenterostomy, enterectomy, etc.), urinary tract obstruction or dysuria, gastroenteritis, peptic ulcer, and history of gastrointestinal bleeding.
  3. Subjects with a history of severe allergic reactions or known to any ingredients of the product.
  4. Subjects with current or previous psychiatric disorders or cerebral dysfunction; those assessed to be at suicide risk based on the Columbia-Suicide Severity Rating Scale (C-SSRS), or by the investigator's clinical assessment, or those with a history of self-harm behavior.
  5. Subjects with a history of substance abuse within 1 year prior to administration or with a positive urine drug screening result.
  6. Subjects with a history of alcohol abuse within 6 months prior to screening (i.e., more than 14 standard units per week; 1 standard unit = 360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine); or with a positive breath alcohol test; or unwilling to abstain from alcohol and any alcohol-containing products from screening until the last PK blood collection.
  7. Subjects with a history of surgery within 3 months prior to screening, or who have not recovered from surgery, or have a planned surgery scheduled during the trial.
  8. Subjects who have donated blood or experienced blood loss ≥ 400 mL within 3 months prior to screening, or ≥ 200 mL within one month, or have a history of blood product transfusion.
  9. Subjects who have participated in any clinical trial and received investigational drugs or medical devices within 3 months prior to screening.
  10. Subjects who have received vaccination within 30 days prior to screening, or have a vaccination plan during the entire study period.
  11. Subjects who have taken any medications within 28 days or 5 half-lives (whichever is longer) prior to screening and during the entire study period, including prescription drugs, over-the-counter drugs, herbal medicines, and any drugs that inhibit or induce hepatic drug-metabolizing enzymes (e.g., inducers and/or inhibitors of , CYP2D6, and CYP3A5).
  12. Female subjects who are pregnant, breastfeeding, or have a positive pregnancy test; or those who refuse to adopt effective non-pharmacological measures (e.g., abstinence, intrauterine device, condoms with vaginal spermicide) throughout the study period and within 28 days after the end of administration; or those with a plan to donate sperm or ova.
  13. Subjects with abnormal findings judged by the investigator in comprehensive physical examination, vital signs, laboratory tests and 12-lead ; including but not limited to: QTc > 450 ms in males and > 470 ms in females (Fridericia correction); resting pulse rate \< 55 beats/min or > 100 beats/min; systolic blood pressure \< 90 mmHg or ≥ 140 mmHg; diastolic blood pressure \< 60 mmHg or ≥ 90 mmHg.
  14. Subjects with non-negative results for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), and Toluidine Red Untreated Serum Test (TRUST).
  15. Subjects with (ALT), creatinine (Cr) or serum prolactin level exceeding 2 times the during the screening period.
  16. Subjects who smoke an average of ≥ 5 cigarettes per day within 3 months prior to screening, or are unable to abstain from any tobacco products during the trial.
  17. Subjects with an average daily intake of ≥ 5 cups of coffee or tea (200 mL per cup) within 3 months prior to screening, or are unable to discontinue intake during the trial.
  18. Subjects with special dietary requirements who cannot follow a unified study diet, or have difficulty in swallowing.
  19. Subjects who have consumed food or beverages containing grapefruit and/or pomelo within 7 days prior to administration.
  20. Subjects who have consumed xanthine-rich food or beverages (e.g., tea, coffee, cola, chocolate) within 3 days prior to administration.
  21. Subjects with poor compliance or other conditions deemed unsuitable for participation in the trial by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Part 1 cohort 1

    SAD Cohort 1: single oral dose of 0.5mg KR23248 capsule

    Drug: KR23248

  • Experimental
    Part 1 cohort 2

    SAD Cohort 2: single oral dose of 1.0mg KR23248 capsule

    Drug: KR23248

  • Experimental
    Part 1 cohort 3

    SAD Cohort 3: single oral dose of 2.0mg KR23248 capsule

    Drug: KR23248

  • Experimental
    Part 1 cohort 4

    SAD Cohort 4: single oral dose of 3.0mg KR23248 capsule

    Drug: KR23248

  • Experimental
    Part 1 cohort 5

    SAD Cohort 5: single oral dose of 4.5mg KR23248 capsule

    Drug: KR23248

  • Experimental
    Part 1 cohort 6

    SAD Cohort 6: single oral dose of 6.0mg KR23248 capsule

    Drug: KR23248

  • Placebo comparator
    Part 1 cohort 7

    SAD cohort 7: single oral dose of placebo capsule

    Drug: Matching Placebo

  • Experimental
    Part 2 KR23248 2.0mg

    MAD: Multiple oral doses of 2.0mg KR23248 capsules administered once daily for 14 consecutive days

    Drug: KR23248

  • Placebo comparator
    Part 2 Placebo

    MAD: Multiple oral doses of placebo capsules administered once daily for 14 consecutive days

    Drug: Matching Placebo

Interventions

  • DrugKR23248

    Participants will recieve a single oral dose of KR23248

    Also known as: KR23248 capsule

  • DrugMatching Placebo

    Participants will recieve placebo

    Also known as: Placebo capsule

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs), serious adverse events(SAEs), drug-related AEs, and AEs leading to study withdrawal

    The number and percentage of participants with AEs,SAEs, drug-related AEs, and AEs leading to study withdrawal will be determined

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

Secondary outcomes

  1. Cmax

    Maximum Serum Concentration

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  2. Tmax

    Time to Reach the Maximum Serum Concentration

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  3. t1/2

    Elimination half-life

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  4. λz

    Terminal rate constant

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  5. AUC0-t

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  6. AUC0-∞

    Area under the plasma concentration-time curve from time zero extrapolated to infinity

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  7. CL/F

    Apparent Clearance

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  8. Vd/F

    Apparent Volume of Distribution

    Time frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

  9. MRT

    Mean residence time

    Time frame: SAD: Day1 to D14 MAD:Day1 to Day28

  10. Css_min

    Steady-state trough concentration

    Time frame: MAD:Day1 to Day28

  11. Css_max

    Steady-state peak concentration

    Time frame: MAD:Day1 to Day28

  12. Tss,max

    Time to Reach Maximum Concentration at Steady State

    Time frame: MAD:Day1 to Day28

  13. Cavg,ss

    Average Steady-State Concentration

    Time frame: MAD:Day1 to Day28

  14. DF

    Fluctuation Percentage

    Time frame: MAD:Day1 to Day28

  15. Rac

    Accumulation Factor

    Time frame: MAD:Day1 to Day28

  16. AUCss

    Area under the plasma concentration-time curve over a dosing interval at steady state

    Time frame: MAD:Day1 to Day28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 6 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartEst.
May 19, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07585383
Responsible party
Sponsor
First posted
May 13, 2026
Start date
May 19, 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
May 15, 2026

Study contacts

Huafang Li
Contact
lhlh_5@163.com
+8618017311256
Yan Li
Contact
liyan7721@163.com
+8613046600636

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion